PROGEN - passion for research

close×

anti-Keratin K19 mouse monoclonal, Ks19.1 (A53-B/A2), lyophilized, purified

Ks19.1 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma.
Cat. No.: 61010
Quantity:  50 µg

Delivery Time: usually 1-7 working days

€201.00
Excl. 19% Tax, excl. Shipping Cost

Call us now for more information on our products: +49 6221 8278-0

Any more questions?
PRODUCT REQUEST

Downloads

Product description

Host mouse
Antibody Type monoclonal
Isotype IgG2a
Clone Ks19.1 (A53-B/A2)
Immunogen Keratin K19 of Mr 40 000; from cultured human MCF-7 cells
Purification protein A affinity chromatography
Conjugate unconjugated
Formulation lyophilized; reconstitute in 1 mL dist. water (final solution contains 0.09 % sodium azide, 0.5% BSA in PBS buffer, pH 7.4)
Storage short term at 2 – 8 °C; long term storage in aliquots at - 20 °C; avoid freeze/ thaw cycles
UniprotID P08727
Tested species reactivity human

Applications

Tested applications Tested dilutions
ELISA assay dependent
Immunocytochemistry (ICC)/ Immunofluorescence (IF) assay dependent
Immunohistochemistry (IHC) - frozen 1:10
Immunohistochemistry (IHC) - paraffin 1:10 (microwave treatment recommended)
Western Blot (WB) assay dependent

Background

Details

Ks 19.1 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma. Polypeptide reacting: Mr 40 000 polypeptide (keratin K19; formerly also designated cytokeratin 19) of human glandular epithelia. The epitope has been localized on aa. 311-335 (QSQLSMKAALEDTLAETEARFGAQL) of the α-helical fragment.

Tumors specifically detected: All tested adenocarcinoma; cholangio carcinoma of liver; renal cell carcinoma; transitional cell carcinoma of the bladder; ovary carcinoma; squamous cell carcinoma of cervix, bronchus and lung (intermediate type); mesothelioma; carcinoid tumor of bronchus; breast carcinoma; thymoma

Reactivity on cultured cell lines: MCF-7, RT 112, Detroit 562, RPMI 2650, HT-29, SSC-12

Reference

Reference

  1. Line Hamelin, C. et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J. 278, 4845–4859 (2011).
  2. Stigbrand, T. et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 19, 132–52 (1998).
  3. Höchtlen-Vollmar, W. et al. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19. Int. J. cancer 70, 396–400 (1997).
  4. Dittadi, R. et al. Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples. Clin. Chem. 42, 1634–8 (1996).
  5. Demirkesen, C., Hoede, N. & Moll, R. Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J. Cutan. Pathol. 22, 518–35 (1995).
  6. Petersen, G., Song, D., Hügle-Dörr, B., Oldenburg, I. & Bautz, E. K. Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Mol. Gen. Genet. MGG 249, 425–31 (1995).
  7. Van Der Gaast ’, A. et al. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br. J. Cancer 69, 525–528 (1994).
  8. Sugama, Y. et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn. J. Cancer Res. 85, 1178–84 (1994).
  9. Pujol, J. L. et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53, 61–6 (1993).
  10. Stieber, P. et al. CYFRA 21-1. A new marker in lung cancer. Cancer 72, 707–13 (1993).
  11. Hasholzer, U. et al. Die klinische Relevanz des neuen Tumormarkers CYFRA 21-1 bei Blasenkarzinomen im Vergleich zu TPA und TPS. LaboratoriumsMedizin 17, 324–327 (1993).
  12. Lindberg, K. & Rheinwaldtt, J. G. Suprabasal 40 kd Keratin (K19) Expression as an Immunohistologic Marker of Premalignancy in Oral Epithelium. Am. J. Pathol. 134, 89–98 (1989).
  13. Balaton, A. J., Nehama-Sibony, M., Gotheil, C., Callard, P. & Baviera, E. E. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J. Pathol. 156, 305–310 (1988).
  14. Dockhorn-Dworniczak, B. et al. Patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas. Differentiation. 35, 53–71 (1987).
  15. Kasper, M., Stosiek, P., Typlt, H. & Karsten, U. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur. J. Cancer Clin. Oncol. 23, 137–47 (1987).
  16. Karsten, U. et al. Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur. J. Cancer Clin. Oncol. 21, 733–40 (1985).
  17. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B. & Krepler, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31, 11–24 (1982).

Material safety data sheet

Please complete the form below to request a material safety data sheet

Personal Info

* Required Fields

Product Request

Personal Info

* Required Fields